Lyell Immunopharma, Inc. (LYEL) Operating cash flow 2019–2025
Lyell Immunopharma, Inc. (LYEL) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$150.0MFY2025 · since FY2019: $39.5M → -$150.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$150.0M | +7.6% |
| FY2024 | -$162.4M | +0.8% |
| FY2023 | -$163.7M | +3.5% |
| FY2022 | -$169.6M | -34.3% |
| FY2021 | -$126.2M | +21.5% |
| FY2020 | -$160.9M | -507.5% |
| FY2019 | $39.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice